WO2009072555A1 - Vaccin contre le cancer - Google Patents

Vaccin contre le cancer Download PDF

Info

Publication number
WO2009072555A1
WO2009072555A1 PCT/JP2008/072046 JP2008072046W WO2009072555A1 WO 2009072555 A1 WO2009072555 A1 WO 2009072555A1 JP 2008072046 W JP2008072046 W JP 2008072046W WO 2009072555 A1 WO2009072555 A1 WO 2009072555A1
Authority
WO
WIPO (PCT)
Prior art keywords
cell
peptide
antigen
cancer vaccine
cytotoxic
Prior art date
Application number
PCT/JP2008/072046
Other languages
English (en)
Japanese (ja)
Inventor
Masahiro Toda
Ryo Ueda
Kozo Tsukada
Original Assignee
Keio University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Keio University filed Critical Keio University
Publication of WO2009072555A1 publication Critical patent/WO2009072555A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464452—Transcription factors, e.g. SOX or c-MYC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Cette invention concerne un peptide comprenant une séquence décrite en SEQ ID NO:1 ou 2 ; une composition comprenant le peptide ; une cellule présentant l'antigène telle qu'une cellule dendritique qui a un antigène dérivé du peptide présenté ici ; et un lymphocyte T tel qu'un lymphocyte T cytotoxique, qui est activé grâce à la cellule présentant l'antigène. Par ailleurs, l'invention concerne un procédé permettant de traiter le cancer en administrant le peptide comprenant une séquence décrite en SEQ ID NO:1 ou 2, la cellule présentant l'antigène ou le lymphocyte T cytotoxique chez un patient cancéreux.
PCT/JP2008/072046 2007-12-04 2008-12-04 Vaccin contre le cancer WO2009072555A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007313856A JP5267969B2 (ja) 2007-12-04 2007-12-04 癌ワクチン
JP2007-313856 2007-12-04

Publications (1)

Publication Number Publication Date
WO2009072555A1 true WO2009072555A1 (fr) 2009-06-11

Family

ID=40717732

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/072046 WO2009072555A1 (fr) 2007-12-04 2008-12-04 Vaccin contre le cancer

Country Status (2)

Country Link
JP (1) JP5267969B2 (fr)
WO (1) WO2009072555A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109952308A (zh) * 2016-11-29 2019-06-28 深圳华大生命科学研究院 多肽及其应用
CN110167956A (zh) * 2016-11-30 2019-08-23 深圳华大生命科学研究院 多肽及其应用
US11813318B2 (en) 2011-04-20 2023-11-14 University Of Washington Beta-2 microglobulin-deficient cells

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010285870A (ja) 2009-06-09 2010-12-24 Denso Corp 筒内圧センサの瞬断検出装置、内燃機関の制御装置
JPWO2012141201A1 (ja) * 2011-04-11 2014-07-28 公立大学法人大阪市立大学 癌免疫療法のためのペプチド及びその利用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003018629A1 (fr) * 2001-08-23 2003-03-06 In2Gen Co., Ltd. Antigene cage
WO2006077941A1 (fr) * 2005-01-19 2006-07-27 Keio University Vaccin contre le cancer
JP2007246451A (ja) * 2006-03-16 2007-09-27 Keio Gijuku 癌ワクチン

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2794370B1 (fr) * 1999-06-03 2003-10-17 Biovector Therapeutics Fragments proteiques polyepitopiques, leur obtention et leurs utilisations notamment en vaccination

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003018629A1 (fr) * 2001-08-23 2003-03-06 In2Gen Co., Ltd. Antigene cage
WO2006077941A1 (fr) * 2005-01-19 2006-07-27 Keio University Vaccin contre le cancer
JP2007246451A (ja) * 2006-03-16 2007-09-27 Keio Gijuku 癌ワクチン

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GOMI, S. ET AL.: "A cyclophilin B gene encodes antigenic epitopes recognized by HLA-A24- restricted and tumor-specific CTLs", J.IMMUNOL., vol. 163, 1999, pages 4994 - 5004 *
OARKER, K.C. ET AL.: "Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side- chains", J.IMMUNOL., vol. 152, 1994, pages 163 - 175 *
RYO UEDA ET AL.: "'Glioma Kogen SOX6 Peptide Vaccine ni yoru Tokuiteki Men'eki Ryoho no Kaihatsu'", SURG.FRONT., vol. 13, no. 2, 2006, pages 49 - 53 *
UEDA, R. ET AL.: "Identification of a human glioma antigen, SOX6, recognized by patients' sera", ONCOGENE, vol. 23, 2004, pages 1420 - 1427 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11813318B2 (en) 2011-04-20 2023-11-14 University Of Washington Beta-2 microglobulin-deficient cells
CN109952308A (zh) * 2016-11-29 2019-06-28 深圳华大生命科学研究院 多肽及其应用
CN109952308B (zh) * 2016-11-29 2022-09-23 武汉华大吉诺因生物科技有限公司 多肽及其应用
CN110167956A (zh) * 2016-11-30 2019-08-23 深圳华大生命科学研究院 多肽及其应用
CN110167956B (zh) * 2016-11-30 2023-04-07 深圳华大生命科学研究院 多肽及其应用

Also Published As

Publication number Publication date
JP2009137857A (ja) 2009-06-25
JP5267969B2 (ja) 2013-08-21

Similar Documents

Publication Publication Date Title
EP2594582A3 (fr) Vaccins de peptide avec Seq Id No: 110, 111, 387, 112, 394 114, 116, 117 ou 121pour cancers exprimant des antigènes associés aux tumeurs
EP2562183A8 (fr) Nouveaux épitopes immunogènes pour lýimmunothérapie
NZ618391A (en) Antigenic tau peptides and uses thereof
WO2009025196A1 (fr) Peptide foxm1 et agent médicinal le comprenant
NZ598458A (en) Hybrid polypeptides including meningococcal fhbp sequences
NZ604089A (en) Multivalent glycopeptide constructs and uses thereof
MX2007008980A (es) Acidos nucleicos para apoptosis de celulas cancerigenas.
NZ590010A (en) Compositions and methods treating growth hormone deficiency and/or an insulin-like growth factor 1 deficiency with somatostatin and an adjuvant
WO2009060281A3 (fr) Analogues d'oligoribonucléotides immunostimulants contenant des fractions oligophosphates modifiées
WO2009038026A1 (fr) Composition inductrice de lymphocytes t cytotoxiques
SG10201407944TA (en) Imp-3 oligopeptides and vaccines including the same
PT1879612E (pt) Utilização de péptidos nativos e de seus derivados optimizados em vacinação
WO2009135199A3 (fr) Compositions vaccinales et procédés
MX2011007963A (es) Peptidos neil3 y vacunas que incluyen los mismos.
WO2009072555A1 (fr) Vaccin contre le cancer
NZ609916A (en) Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
WO2008019888A3 (fr) Pax2 et pax8 en tant que cibles tumorales dans des stratégies de traitement immunologique ou moléculaire
WO2011053789A3 (fr) Composition pharmaceutique et procédés pour améliorer la reconnaissance de lymphocytes t cytotoxiques et maintenir la mémoire à lymphocytes t contre une maladie pathogène
WO2009066462A1 (fr) Procédé pour l'induction d'un lymphocyte t cytotoxique, inducteur de lymphocyte t cytotoxique et composition pharmaceutique et vaccin comprenant chacun l'inducteur
EP1592443A4 (fr) Ameliorations apportees a des vaccins contre l'anthrax et methodes d'administration
NZ592461A (en) Rab6kifl/kif20a epitope peptide and vaccines containing the same
CA2819463C (fr) Peptides tomm34 et vaccins les comprenant
EP3208334A3 (fr) Peptides cdc45l et vaccins les comportant
MX2011008917A (es) Peptidos vangl1 y vacunas que incluyen los mismos.
NZ600978A (en) Vaccine compositions

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08856565

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08856565

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)